Tscan Therapeutics is trading 5.1% down at $0.85 as shares move lower alongside a weak broader market and pressured growth/biotech sentiment.
- There are no fresh company-specific headlines, earnings, FDA decisions, or analyst calls tied directly to today's move.
- The drop appears primarily driven by risk-off trading in smaller healthcare and biotech names as major indices slide.